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Craniofacial morphogenesis is regulated in part by signaling from the Endothelin receptor type A 
(EDNRA). Pathogenic variants in EDNRA signaling pathway components EDNRA, GNAI3, PCLB4 
and EDN1 cause Mandibulofacial Dysostosis with Alopecia (MFDA), Auriculocondylar syndrome 
(ARCND) 1, 2 and 3, respectively. However, cardiovascular development is normal in MFDA and 
ARCND individuals, unlike Ednra knockout mice. One explanation may be that partial EDNRA 
signaling remains in MFDA and ARCND, as mice with reduced, but not absent, EDNRA signaling 
also lack a cardiovascular phenotype. Here we report an individual with craniofacial and 
cardiovascular malformations mimicking the Ednra-/- mouse phenotype, including a distinctive 
micrognathia with microstomia and a hypoplastic aortic arch. Exome sequencing found a novel 
homozygous missense variant in EDNRA (c.1142A>C; p.Q381P). Bioluminescence resonance energy 
transfer assays revealed that this amino acid substitution in helix 8 of EDNRA prevents recruitment of 
G proteins to the receptor, abrogating subsequent receptor activation by its ligand, Endothelin-1. This 
This article is protected by copyright. All rights reserved.
homozygous variant is thus the first reported loss-of-function EDNRA allele, resulting in a syndrome 
we have named Oro-Oto-Cardiac Syndrome. Further, our results illustrate that EDNRA signaling is 
required for both normal human craniofacial and cardiovascular development, and that limited 
EDNRA signaling is likely retained in ARCND and MFDA individuals. This work illustrates a 
straightforward approach to identifying the functional consequence of novel genetic variants in 
signaling molecules associated with malformation syndromes. 
 
KEYWORDS: Neural crest cell, micrognathia, cardiovascular, Auriculocondylar syndrome, BRET,  
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Introduction 
Endothelin receptor type A (EDNRA, encoded by EDNRA [MIM 131243]) is a G protein-coupled 
receptor that is essential for development of the craniofacial complex and portions of the 
cardiovascular system (Clouthier et al., 1998; Nair, Li, Cornell, & Schilling, 2007). This process is 
mediated by EDNRA signaling-dependent patterning of the cranial and cardiac neural crest cells in the 
pharyngeal arches (Abe, Ruest, & Clouthier, 2007; Clouthier, Williams, Hammer, Richardson, & 
Yanagisawa, 2003; Clouthier et al., 2000; Miller, Yelon, Stainier, & Kimmel, 2003; Ozeki, Kurihara, 
Tonami, Watatani, & Kurihara, 2004; Ruest, Xiang, Lim, Levi, & Clouthier, 2004). In mice, genetic 
ablation of the receptor (Ednra-/-), ligand (Endothelin-1, Edn1-/-), ligand-processing enzyme 
(Endothelin converting enzyme 1, Ece1-/-), or primary signaling effectors (G protein α subunits Gq and 
G11, Gnaq-/-;Gna11-/-) result in severe defects in the mandible and ears and neonatal lethality from 
mechanical asphyxia (Clouthier et al., 1998; Dettlaff-Swiercz, Wettschureck, Moers, Huber, & 
Offermanns, 2005; Kurihara et al., 1994; Offermanns et al., 1998; Yanagisawa et al., 1999; 
Yanagisawa et al., 1998). A characteristic defect of endothelin signaling loss is the homeotic 
transformation of most mandible structures into maxillary-like structures (Ozeki et al., 2004; Ruest et 
al., 2004). These mice also exhibit cardiovascular defects that include interruption of the aorta and 
ventricular septal defects (VSD) (Clouthier et al., 1998, Yanagisawa et al., 1999; Yanagisawa et al., 
1998). However, craniofacial and cardiovascular development appears differentially sensitive to loss 
of EDNRA signaling. In Ednra+/+ <->Ednra-/- chimeras, in which tagged Ednra-/- embryonic stem 
(ES) cells are injected into wild type blastocysts, the extent of craniofacial differences increased 
proportionally with the increasing contribution of Ednra-/- ES cell-derived cells to the developing 
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embryo (Clouthier et al., 2003). However, cardiovascular differences were only seen in one embryo 
with the highest percentage of Ednra-/- ES cell-derived cells. These findings indicate that while 
EDNRA signaling is required for both craniofacial and cardiovascular development, cardiovascular 
development likely can withstand a greater disruption in EDNRA signaling (Clouthier et al., 2003). 
 In humans, pathogenic variants in signaling components of the EDNRA pathway are linked to 
craniofacial disorders characterized by mandible and ear malformations similar to Edn1/Ednra 
knockout mice, highlighting the evolutionary conservation of EDNRA signaling in craniofacial 
development (Table 1). Auriculocondylar syndrome 1 [ARCND1; MIM 602483] and ARCND2 [MIM 
614669] are autosomal dominant disorders resulting from pathogenic variants in EDNRA downstream 
signaling components PLCB4 [MIM 600810] and GNAI3 [MIM 139370], respectively (Rieder et al., 
2012). ARCND3 is an autosomal recessive disorder resulting from biallelic pathogenic variants in 
EDN1 (Gordon et al., 2013). Heterozygous pathogenic variants of EDN1 lead to the autosomal 
dominant disorder Question Mark Ears, Isolated (QME; MIM 612798). Mandibulofacial Dysostosis 
with Alopecia [MFDA; MIM 616367] results from gain-of-function variants in EDNRA and appears 
to be inherited in an autosomal dominant fashion (Gordon et al., 2015). The functional consequences 
of a given MFDA pathogenic variant is complex, as in the upper jaw, there is likely aberrant EDNRA 
signaling, while in the lower jaw, there appears to be disruption of EDNRA signaling (Gordon et al., 
2015). However, unlike Edn1/Ednra knockout mice (Clouthier et al., 1998; Kurihara et al., 1994), 
individuals with ARCND and MFDA do not present with cardiovascular defects, suggesting that 
limited EDNRA signaling likely remains in affected individuals.  
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 In this study, we have identified a homozygous variant in EDNRA inherited in an autosomal 
recessive manner that results in craniofacial and cardiovascular malformations leading to neonatal 
lethality. This is the first patient known to be affected with this condition, which more closely 
resembles the phenotype of Ednra-/- mice than MFDA and ARCND individuals. To determine the 
functional consequence of this variant, we used a variety of molecular and cell biological reporter 
assays including a series of bioluminescence resonance energy transfer (BRET) assays. We find that 
the variant disrupts EDNRA-G protein interactions but not protein folding or receptor localization. 
Our results provide a mechanistic basis for a novel pathogenic variant in EDNRA that likely results in 
significant reduction of EDNRA signaling in NCCs during craniofacial and cardiovascular 
development.  Furthermore, our approach demonstrates the modularity and adaptability of BRET 




Materials and Methods 
Editorial policies and ethical considerations. 
 
The subject’s parents provided consent for publication of this case and photographs. No experimental 
procedures involving human and/or animal subjects were performed. 
 
Clinical exome sequencing 
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Clinical exome sequencing was performed on the proband and both unaffected parents essentially as 
previously described (Gibson et al., 2018). Exome libraries were prepared using the SureSelect 
Clinical Research Exome kit (CRE v1), following the manufacturers protocol (Agilent Technologies, 
Santa Clara, CA). Sequencing was performed on a HiSeq2500 (Illumina, San Diego, CA). Following 
exome sequencing, reads were aligned to the reference human genome (GRCh37/hg19) and variants 
called with an in-house-developed bioinformatics pipeline that incorporated NovoAlign (Novacraft) 
for read alignment, Picard (broadinstitute.github.io/picard/) for duplicate marking and the Genome 
Analysis Toolkit (software.broadinstitute.org/gatk/) for variant calling. Variants exceeding a total 
minor allele frequency of 0.2% in the Exome Aggregation Consortium database were excluded from 
analysis, with the exception of a predefined list of known pathogenic variants in genes associated with 
autosomal recessive conditions that exceed these thresholds. All remaining variants were reviewed for 
overlap with the proband’s clinical phenotype. All de novo, hemizygous, homozygous and compound 
heterozygous variants received an additional level of clinical review, with special attention paid to 
variants residing in the ROH previously identified by array. The variant identified in EDNRA was 





The human EDNRA expression construct (pCMV6-XL5-EDNRA) was purchased from Origene. The 
p.Q381P variant was introduced into pCMV6-XL5-EDNRA using the QuickChange Lightning Site-
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Directed Mutagenesis Kit (Agilent Technologies) and primers 5’ 
GAAATTTAAAAATTGTTTCCCGTCATGCCTCTGCTGCTGC 3’ and 
5’ GCAGCAGCAGAGGCATGACGGGAAACAATTTTTAAATTTC 3’ to change the A at 
nucleotide position 1142 to a C, thus changing the glutamine (Q) at aa 381 to a proline (P). These 
plasmids are referred to as pCMV-EDNRA (or wild type EDNRA) and pCMV-EDNRA p.Q381P. 
pEDNRA-RLuc8 was constructed by subcloning a myc-EDNRA fragment derived from pmyc-
EDNRA-GFP (pmyc-ETA-GFP), a kind gift from Jeffery Walker, University of Wisconsin) using 
HindIII and AgeI. pEDNRA-RLuc8 p.Q381P was derived from EDNRA-RLuc8 using the 
QuickChange Lightning Site-Directed Mutagenesis Kit as described above. pcDNA3.1-VN-Gγ2, 
pcDNA3.1-VC-Gβ1, pNES-Venus-mG, pVenus-kras, pVenus-PTP1b, pVenus-giantin have been 
previously described (Hollins, Kuravi, Digby, & Lambert, 2009 Masuho, 2015 #2272; Wan et al., 
2018). pcDNA3-Gαq-HA was a kind gift by P. Wedegaertner (Wedegaertner, Chu, Wilson, Levis, & 
Bourne, 1993). pcDNA3.1-masGRK3ct-Nluc was a kind gift from Kirill Martemyanov (Masuho, 
Ostrovskaya, et al., 2015). mCherry-MEM was purchased from Addgene (plasmid 55779, deposited 
by Catherine Berlot) (Yost, Mervine, Sabo, Hynes, & Berlot, 2007). All constructs were verified by 
Sanger sequencing. 
 
Cell culture and transfection 
MC3T3-E1 cells (ATCC) were cultured in MEM alpha (Invitrogen) supplemented with 20% fetal 
bovine serum (Sigma). HEK293 and HEK293T cells (ATCC) were cultured in DMEM (Corning) 
supplemented with 10% fetal bovine serum.  All cell types were grown at 37°C with 5% CO2 in a 
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humidified incubator. Transient transfections were performed with X-tremeGENE 9 (Roche) or linear 
polyethyleneimine; MW 25,000 (Polysciences Inc.). A 3:1 ratio of X-tremeGENE 9 (µl) to plasmid 
DNA (µg) was used, and 1µg of plasmid DNA was used for one well of a 6-well plate. Linear 
polyethyleneimine was used at an N/P ratio of 20, and up to 3 μg of plasmid DNA was transfected in 
one well of a 6-well plate. All transfections were monitored for relative transfection efficiency by 
qualitatively examining Venus fluorescence. To ensure similar transfection efficiencies between 
EDNRA-RLuc8 and EDNRA-RLuc8 p.Q381P, raw luciferase values were examined following each 
experiment, with no statistically significant difference observed between the two constructs (Supp. 
Figure 1A). In addition, by comparing the number of fluorescent cells vs total cells in representative 
transfections (n=3 for each condition), we found that the transfection efficiencies of mGsq-Venus, 
Gβγ-Venus, EDNRA-GFP and EDNRA-GFP p.Q381P was >67% for all vectors, with no statistically 
significant difference observed between the vectors (Supp. Figure 1B). 
 
Quantitative real-time PCR assays 
MC3T3-E1 cells were transiently transfected with pCMV6-EDNRA, pCMV6-EDNRA p.Q381P or 
pCS2 empty vector using X-tremeGENE9 for six hours before exchanging transfection media for 
serum free media. 24-36 hours after transfection, cells were treated with 5 nM EDN1 and 10 µM BQ-
788 (EDNRB-specific antagonist) for 1 hour before collecting RNA with Direct-zol (Zymogen). 
cDNA was prepared from total RNA with the QuantiTect cDNA Synthesis Kit (Qiagen) and qRT-PCR 
performed with 5 ng of cDNA using the QuantiTect SYBR Green PCR kit (Qiagen) and QuantiTect 
Assay Primers for Actb, Dlx2 and Dlx5 (Qiagen) on a CFX Connect Real-time PCR Detection System 
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(Bio-Rad). All assays were performed in triplicate at least three times. Statistical analysis was 
conducted using Prism, with significance calculated using an unpaired two-tailed t-test.  
 
G protein activation assays: HEK293T cells were transiently transfected with X-tremeGENE 9. 
pCMV6-EDNRA or pCMV6-EDNRA p.Q381P, along with pcDNA3-Gαq-HA, Venus155-239-Gβ1, 
Venus1-155-Gγ2 and masGRK3ct-Nanoluc were transfected at a 1:2:1:1:1 ratio (Masuho, 
Martemyanov, & Lambert, 2015). For control experiments, pcDNA3.1 empty vector was substituted 
for pCMV6-EDNRA. 24 hours later, cells were harvested and resuspended in reaction buffer 
(Tyrode’s salt solution with 0.1% glucose) as previously described (Masuho, Martemyanov, et al., 
2015). 25,000 cells were added into individuals wells of an opaque 96-well plate (Perkin Elmer) and 
incubated with the Nanoluc luciferase substrate Furimazine (Promega) for 3 minutes prior to assay. 
BRET assays were performed in a Synergy 2 microplate reader (Biotek) equipped with emission filters 
for Venus (485/20 nm, reading 475-495 nm) and Nanoluc (528/20 nm, reading 518-538 nm). After a 
1-minute measurement of basal BRET, EDN1 was added at a final concentration of 1 µM and BRET 
was measured for another 3 minutes. BRET measurements were made by automatic filter-switching 
every 2 seconds. Raw BRET signals were calculated as the emission intensity at 528/20 nm divided by 
the emission intensity at 485/20 nm. Delta BRET was calculated by subtracting the average raw BRET 
ratio signal before EDN1 from the individual raw BRET values. All assays were performed at least 
three times, with each assay measured in triplicate, with statistical analysis conducted using Prism. 
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Subcellular localization and miniG protein assays: HEK293 cells were transfected with linear 
polyethyleneimine, and 12-48 hours later cells were washed with DPBS, harvested by trituration, and 
transferred to opaque black 96-well plates. Cells were exposed to either EDN1 (1 µM) or vehicle (1% 
bovine serum albumin). Coelenterazine h (5 µM; Nanolight, Pinetop, AZ) was added to all wells 
immediately prior to making measurements using a Mithras LB940 photon-counting plate reader 
(Berthold Technologies GmbH, Bad Wildbad, Germany). Raw BRET signals were calculated as the 
emission intensity at 520-545 nm divided by the emission intensity at 475-495 nm. Net BRET was 
calculated as this ratio minus the same ratio measured from cells expressing only the BRET donor. All 
assays were performed at least three times, with statistical analysis was conducted using Prism. 
 
Live confocal microscopy 
HEK293T cells were plated onto poly-D lysine coated glass bottom dishes (MatTek) and co-
transfected with mCherry-MEM and pcDNA3.1 (mock), pCMV-EDNRA (wild type) or pCMV-
EDNRA p.Q381P constructs using X-tremeGENE9. 6 hours later, growth medium was replaced with 
serum-free medium. 24 hours after initial transfection, live confocal microscopy was performed with a 
Leica TCS SP5 and 63X oil objective. Line scans were performed for 2 minutes prior and 10 minutes 
after addition of HiLyte Fluor 488-ET1 (HiLyte-Fluor 488-ET-1 (EDN1); 100 nM final concentration; 
Anaspec) to cells. HiLyte Fluor 488 is a proprietary fluorophore with similar excitation and emission 
spectra as fluorescein. 
 
Fluorescent ligand binding assay 
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HEK293T cells were transfected in a 6-well dish with pcDNA3.1 empty vector, EDNRA or EDNRA 
p.Q381P constructs using X-tremeGENE9. 24 hours later, cells were dissociated and plated into 
individual wells of a poly-D lysine-coated black wall clear bottom 96-well dish (Corning) in serum-
free growth medium at a concentration of 75,000 cells/well. 12-24 hours after plating, cells were 
incubated with or without 100 nM HiLyte-EDN1 in Tyrode’s Buffer (Sigma) supplemented with 0.1% 
glucose and 0.04% bovine serum albumin for 20 minutes at room temperature. Cells treated with the 
EDNRA-specific antagonist BQ-123 (Sigma) were incubated for 5 minutes prior to Hylite-488-EDN1 
addition. Cells were washed once, replaced with Tyrode’s Buffer and assayed immediately in a 
Synergy 2 microplate reader fitted with a 485/20 nm excitation filter, 528/20 emission filter and 500 
nm cut-off dichroic mirror. Specific fluorescence was calculated by subtracting background 
fluorescence (cells without HiLyte-EDN1) from raw fluorescence values. All assays were performed 
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A 31-year-old Caucasian gravida 3 para 0 woman was initially seen at 25 weeks of gestation due to 
multiple fetal anomalies noted on ultrasound. The pregnancy was conceived through in vitro 
fertilization due to prior salpingectomy. There was a history of one first trimester pregnancy loss and 
one ectopic pregnancy. There were no unusual exposures during this pregnancy. Prenatal ultrasound at 
19 weeks, 6 days gestation revealed micrognathia, polyhydramnios, choroid plexus cyst, and a 
suspected ventricular septal defect (VSD). Ultrasound at 25 weeks of gestation additionally found 
glossoptosis, elongated philtrum, small fetal stomach, microtia, suspected aortic stenosis, and mild 
pectus excavatum. Head size and extremities appeared normal. Fetal echocardiogram at 25 weeks was 
notable for a large VSD and hypoplastic aortic arch, though ventricular size and systolic function were 
normal. An amniocentesis was performed at 23 weeks of gestation and a single nucleotide 
polymorphism (SNP) microarray was performed from cultured amniocytes. While the microarray 
revealed no copy number abnormalities, a single region of homozygosity in 4q31.21-q31.23 
arr[hg19](142,917,034-150,426,641) was present and covered 7.51 Mb. Family history was generally 
unremarkable; both parents were healthy and no consanguinity was known. Amnioreduction was 
required at 27 weeks, 2 days gestation. The pregnancy was also complicated by a maternal history of 
short cervix necessitating indomethacin treatment. Preterm labor subsequently commenced. 
The male infant was born via vaginal delivery at 27 weeks, 3 days gestation weighing 879 grams (25th 
percentile for gestational age), with a length of 26 cm (30th percentile) and head circumference of 25 
cm (25th percentile). The infant could not be orally intubated but was successfully nasally intubated. 
However, he suffered an acute decompensation event with bradycardia and hypoxemia that was 
unresponsive to resuscitation at 10 hours of life. Physical and autopsy examination found a wide 
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variety of craniofacial and cardiovascular malformations (Fig. 1A, B and Table 2). These included 
distinctive micrognathia and microstomia with an inability to fully open the mouth, aglossia, and 
significant ear abnormalities. Computerized tomography (CT) scan of the mandible was not performed 
due to the short time frame in which the individual was in the neonatal intensive care unit. Cardiac 
outflow tract defects were also present (Table 2). Extremities were normal and no abnormalities of the 
liver, kidneys, genitalia, nor other intra-abdominal structures were noted. Brain autopsy was normal 
with exception of a germinal matrix hemorrhage, likely related to gestational age. 
 The initial differential diagnosis was limited, as the infant’s features did not fit previously 
described syndromes. The oral and jaw abnormalities were not consistent with Treacher Collins 
Syndrome (TCS1; MIM 154500). Agnathia-otocephaly complex (AGOTC; MIM 202650) was also 
considered, though the ears were not as displaced as may be expected. The dysmorphia seemed too 
significant to fall within the oculo-auriculo-vertebral spectrum (OAVS: MIM 164210), and the 
absence of question mark ear (QME) and presence of cardiovascular defects ruled out 
Auriculocondylar Syndrome 1-3 (ARCND1-3). In order to identify a possible underlying genetic 
etiology of this patient’s phenotype, trio clinical exome sequencing was performed.  
 
Molecular studies 
Clinical whole exome sequencing revealed rare homozygous variants in the EDNRA [MIM 131243] 
and FREM3 [MIM 608946] genes, both of which reside in the region of homozygosity on 
chromosome 4q31.21-q31.23. FREM3, encoding a basement membrane protein involved in the 
integrity of early embryonic skin (Pavlakis, Makrygiannis, Chiotaki, & Chalepakis, 2008), has not 
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been associated with either Mendelian disease to date or in isolated craniofacial or cardiovascular 
development/disorders, though polymorphisms in FREM3 have been linked to major depressive 
disorders and differential susceptibility to severe malaria (Manjurano et al., 2015; Shi, Zhang, Wang, 
Shen, & Xu, 2012). In addition, the identified variant in the FREM3 transcript (NM_ 001168235.1, 
c.2192T>C; p.I1731T; dbSNP rs1450255129) is a conservative missense substitution at a weakly 
conserved residue, with threonine observed in multiple mammalian species (Lek et al., 2016) and with 
a minor allele frequency of 0.136% in the South Asian population (Karczewski et al., 2019). Thus, this 
variant was deemed not relevant to the clinical indication for the exome and was not included in the 
report. 
 The homozygous EDNRA variant (NM_00157.3, c.1142A>C; p.Q381P; dbSNP rs1219791712) 
results in a glutamine to proline change in helix 8 of EDNRA (Fig. 1C). Biparental inheritance was 
confirmed via exome sequencing, ruling out uniparental disomy as the cause of the region of 
homozygosity (Fig. 1D). While the variant resides at the -2 position from the exon 7 splice donor site, 
computational algorithms predict a weak to moderate effect on the splice donor site (data not shown). 
This variant is absent from the Exome Aggregation Consortium (ExAC) and Genome Aggregation 
Consortium (gnomAD) databases (data not shown) (Lek et al., 2016). Moreover, while not at the level 
of statistical significance, EDNRA may be intolerant of coding alterations and loss-of-function 
alterations (gnomAD z=2.93, pLI=0.99), making the identification of a novel missense variant highly 
significant. Based on the limited available data for this variant and absence of previous description of a 
craniofacial disorder caused by autosomal recessively inherited pathogenic variants in EDNRA, the 
p.Q381P variant was clinically interpreted by the diagnostic laboratory as a variant of uncertain 
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significance. No other rare variants in genes that overlap with clinically verified disease-associated 
alleles were identified. Moreover, no other variants meeting a Mendelian mode of inheritance with 
plausible causality for the phenotypes described in this patient were identified, including homozygous, 
compound heterozygous, X-linked, de novo or variants in imprinted genes (data not shown). There 
were no variants noted in genes known to cause structural heart differences. 
 To determine whether this variant affects EDNRA function in a developmental context, we 
examined EDNRA-dependent gene expression. The earliest known gene expression regulatory event 
following EDNRA activation is induction of Dlx5 and Dlx6 expression in the ventral mandibular 
arches (Charité et al., 2001; Clouthier & Schilling, 2004; Clouthier et al., 2000; Tavares et al., 2012). 
Dlx genes encode homeobox transcription factors crucial for cranial neural crest cell (NCC) patterning 
(Depew, Simpson, Morasso, & Rubenstein, 2005), with Dlx5/Dlx6 expression required for establishing 
ventral NCC identity in the mandibular arches (Depew, Lufkin, & Rubenstein, 2002). This is in 
contrast to Dlx1/Dlx2, which are expressed in the dorsal mandibular arch but are repressed in the 
ventral arch by EDNRA signaling (Ruest et al., 2004). We transfected either wild type EDNRA or the 
p.Q381P variant into MC3T3 cells, a mouse pre-osteoblastic cell line with a genomic profile that 
closely resembles cranial NCC-derived mesenchymal cells (Tavares, Cox, Maxson, Ford, & Clouthier, 
2017). Addition of EDN1 to the transfected cells expressing wild type EDRNA resulted in a 1.75-fold 
induction of Dlx5 (Fig. 2A), while Dlx5 expression after EDN1 addition was not induced in cells 
expressing the p.Q381P variant (Fig. 2A). In an opposite manner, addition of EDN1 to the transfected 
cells expressing wild type EDRNA resulted in a 1.58-fold reduction in Dlx2, while Dlx2 expression 
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after EDN1 addition was not repressed in cells expressing the p.Q381P variant (Fig. 2B). Together, 
these results suggest that the p.Q381P variant represents a strong loss-of-function allele. 
 Like other class A GPCRs, EDNRA is composed of an N-terminal extracellular domain, seven α-
helical transmembrane (7-TM) domain and a C-terminal cytoplasmic domain that contains an eighth 
amphipathic helix (helix 8) that lies immediately after the seventh transmembrane domain. The role of 
helix 8 in EDNRA function has not been directly assessed, though helix 8 in other class A GPCRs is 
required for functions that include receptor localization(Feierler et al., 2011; Karpinsky-Semper et al., 
2015), receptor desensitization and internalization (Faussner et al., 2005; Kirchberg et al., 2011) and G 
protein coupling (Delos Santos, Gardner, White, & Bahouth, 2006; Scheerer et al., 2008). Because a 
single proline substitution in an α helix can distort structure and disrupt normal function (Piela, 
Nemethy, & Scheraga, 1987; Yang et al., 1997), we hypothesized that the p.Q381P variant affects 
helix 8-dependent receptor properties.  
 We first assessed whether the p.Q381P variant resulted in mislocalization of EDRNA by 
examining the relative distribution of EDNRA in the plasma membrane and endo-membrane 
compartments using a bioluminescence resonance energy transfer (BRET) assay (Lan, Liu, Li, Wu, & 
Lambert, 2012). BRET assays report the physical proximity of a fluorescent acceptor (in our assays, 
the yellow fluorescent protein Venus) and a bioluminescent protein donor (in our assays, either Renilla 
or Nanoluc luciferases (Promega))(Hamdan, Percherancier, Breton, & Bouvier, 2006). The emission 
wavelength of luciferase overlaps with the Venus excitation wavelength; therefore, in the presence of 
luciferase substrate, the close proximity of the donor-acceptor pair results in energy transfer and Venus 
fluorescence emission, which is referred to as BRET response (Fig. 3A and data not shown). By 
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tagging Venus and luciferase to different proteins of interest and subsequently measuring BRET, many 
aspects of cellular processes can be examined. Cellular localization of EDNRA was examined using 
BRET donor-tagged membrane compartment markers Venus-kras (plasma membrane), Venus-PTP1b 
(endoplasmic reticulum) and Venus-giantin (Golgi apparatus) (Lan et al., 2012) (Fig. 3A). These 
markers were used in combination with Renilla luciferase variant 8-tagged EDNRA (EDNRA-RLuc8) 
as the BRET donor. BRET levels for wild type EDNRA and the p.Q381P variant were similar for all 
three cellular compartments, indicating that the p.Q381P variant did not impact overall cellular 
localization (Fig. 3B).  
 We next determined whether ligand binding was affected by the p.Q381P variant. EDN1 binds to 
the ligand-binding pocket in the 7-TM domain, which results in conformational changes to the 
transmembrane α-helices and cytoplasmic domains that facilitate G protein coupling and activation 
(Weis & Kobilka, 2018). Because of the allosteric mechanism that links the ligand-binding pocket and 
intracellular G protein coupling domains (DeVree et al., 2016; Gregorio et al., 2017; Huang et al., 
2015; Yao et al., 2009), we examined whether the p.Q381P variant affects EDN1-binding. To assess 
this, we examined fluorophore-tagged EDN1 (HiLyte-ET1) binding with wild type EDNRA and the 
EDNRA p.Q381P variant. Using live confocal microscopy, we observed rapid membrane association 
of HiLyte-EDN1 following its addition in HEK293T cells expressing wild type EDNRA (Fig. 3C) 
(HEK293T cells do not express EDNRA; data not shown). Similarly, rapid membrane association was 
observed in cells expressing the p.Q381P variant (Fig. 3C). Further, when HEK293T cells were treated 
as above and assayed with a fluorescent plate reader, overall fluorescence was not statistically 
significant between cells expressing wild type or p.Q381P variant EDNRA constructs (Fig. 3D). These 
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data indicate that both EDNRA and EDNRA p.Q381P are present at similar levels and that the 
p.Q381P variant does not affect EDN1 binding to EDNRA. Furthermore, these data suggest that 
general protein folding is not drastically altered by the p.Q381P variant.  
 These results suggest that the p.Q381P variant affects EDNRA signaling downstream of ligand 
binding. GPCR signaling is mediated by a heterotrimeric G protein complex that is composed of a Gα 
subunit and an obligate Gβγ dimer (Gilman, 1987). Ligand binding to a GPCR initiates the rate-
limiting step of G protein activation, in which GDP is exchanged for GTP in the Gα subunit. This 
exchange results in the dissociation of Gα and Gβγ and activation of their respective downstream 
signaling effectors (Gilman, 1987). Gq activates phospholipase C beta isoforms (PLCB) (Smrcka, 
Hepler, Brown, & Sternweis, 1991), while the Gβγ dimer binds to several different effectors as well as 
G protein-coupled receptor kinase (GRK)(Daaka et al., 1997). To determine whether the p.Q381P 
variant impairs G protein activation, we measured the Gαβγ dissociation event as an indirect reporter 
of EDNRA-mediated G protein activation. For our assay, we used Venus-Gβγ as the BRET acceptor, 
in which GβV1 and GγV2 encode complementary fragments that reconstitute Venus upon heterodimer 
formation of Gβγ (Hynes et al., 2004). The BRET donor was the Gβγ binding domain of G protein-
coupled receptor kinase 3 (GRK3), fused to Nanoluc luciferase (masGRKct-Nanoluc, BRET donor) 
(Masuho, Ostrovskaya, et al., 2015) (Fig. 4A). Cells transfected with wild type EDRNA produced high 
BRET activity in response to addition of EDN1, indicating dissociation of Gαβγ and subsequent 
association of Venus-Gβγ with masGRK3ct-Nluc (Fig. 4B). However, cells expressing the p.Q381P 
This article is protected by copyright. All rights reserved.
variant produced significantly diminished BRET activity after EDN1 addition, indicating that Gq 
protein activation was impaired.  
 The EDNRA receptor couples promiscuously to several different Gα isoforms, including Gαq, 
Gαi, and Gα12 (IUPHAR database). We therefore tested whether coupling of several G protein 
isoforms to the EDRNA p.Q381P variant is disrupted. We took advantage of mini-G (mG) proteins, 
which lack the ability to bind Gβγ and contain a mutation that stabilizes the GPCR-mG association, 
making them ideal reporters for analyzing G protein-GPCR interactions (Wan et al., 2018). Gq 
interaction was examined using Venus-tagged mGsq (Venus-mGsq), a chimeric protein that has the 
stability of mGs but binding specificity of mGq (Wan et al., 2018), and wild type- or p.Q381P-
EDNRA-RLuc8 (BRET donor) (Fig. 5A). Cells expressing Venus-mGsq and EDNRA-RLuc8 
produced high BRET activity after EDN1 addition (Fig. 5B). However, cells expressing Venus-mGsq 
and EDNRA-RLuc8 p.Q381P produced significantly diminished BRET activity after EDN1 addition, 
suggesting that Gq-EDNRA interaction is disrupted by the p.Q381P variant (Fig. 5B). Additionally, 
using Venus-tagged mG proteins for Gi (mGi), Gs (mGs) and G12 (mG12), we found that cells 
expressing EDNRA-RLuc8 produced EDN1-induced BRET activity for all G protein classes, although 
they bound less well compared to mGsq (Fig. 5B). However, BRET activity was significantly 
diminished in cells expressing EDNRA-RLuc8 p.Q381P and mGi or mGs after EDN1 addition. 
Although EDN1-induced BRET activity was diminished for G12, no statistically significant difference 
was observed. Taken together, the results indicate that the p.Q381P variant disrupts overall G protein-
EDNRA interactions. 
 





Here we report the first known autosomal recessively inherited pathogenic variant in EDNRA that acts 
as a strong loss-of-function allele. This variant leads to malformation of craniofacial and 
cardiovascular structures consistent with early NCC patterning defects due to loss of EDNRA 
signaling. While we cannot rule out that one or more genetic variants not detected by exome 
sequencing contributed to the observed phenotype, based on the overall phenotypic similarities 
between this individual and Endothelin pathway mouse mutants, we believe that the observed defects 
in our individual result solely from the EDNRA variant. Furthermore, these phenotypic similarities 
highlight the evolutionary conservation of EDNRA signaling during patterning of the craniofacial 
complex (Clouthier, Garcia, & Schilling, 2010; Clouthier et al., 2013; Medeiros & Crump, 2012). It is 
possible that prior human pregnancies have been affected by loss-of-function variants of EDNRA but 
were never genetically investigated due to the lack of viability in the setting of airway stenosis. 
Notably this case constitutes a recognizable, unique phenotype that we have named Oro-Oto-Cardio 
syndrome.  
 EDNRA signaling is required for both cranial and cardiac NCC patterning (Clouthier et al., 1998; 
Kurihara et al., 1994; Yanagisawa et al., 1999). To date, only two other variants in EDNRA (p.Y129F, 
p.E303K) have been described that results in craniofacial anomalies, both in individuals with MFDA, 
though the absence of cardiovascular defects suggests that neither variant results in a complete loss of 
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EDNRA signaling (Gordon et al., 2015). In actuality, the functional consequence of the p.Y129F 
variant in MFDA individuals is complex. The p.Y129 residue is responsible for limiting activation of 
EDNRA to EDN1, with a p.Y129F change leading to the ability of EDN3 to also bind to the receptor 
(Krystek et al., 1994; Lee et al., 1994). MDFA individuals have maxillary changes suggesting earlier 
inappropriate EDNRA signaling in the maxillary portion of the first arch, while retrognathia and 
middle ear abnormalities indicate loss of EDNRA signaling in the mandibular portion of arch 
one.(Gordon et al., 2015). Importantly, MDFA patients do not have cardiovascular defects exhibited 
by Edn1/Ednra/Ece1 knockout mice (Clouthier et al., 1998; Dettlaff-Swiercz et al., 2005; Kurihara et 
al., 1995; Offermanns et al., 1998; Yanagisawa et al., 1998). In stark contrast, the p.Q381P variant 
described in this study caused a severe reduction in Gq coupling (Fig. 5B) and activation (Fig. 4C), 
which likely resulted in a complete loss of EDNRA signaling in NCCs that give rise to the lower jaw 
structures, ears, and smooth muscle of the cardiac outflow tract. 
 Like MFDA, individuals with ARCND have facial phenotypes resembling those in Ednra-/- 
embryos but lack cardiovascular defects. The minimum level of EDNRA signaling required for 
cardiac development is not known. However, as described above, chimera analysis in mice, in which 
wild type and Ednra-/- ES cells are mixed, has provided some idea about the difference in sensitivity to 
loss of EDNRA signaling between cranial and cardiac NCCs (Clouthier et al., 2003). These 
experiments showed that EDNRA signaling occurs cell autonomously within both cranial and cardiac 
NCCs. However, all Ednra+/+<->Ednra-/- chimeric embryos had some degree of facial difference, with 
the severity higher in embryos with a higher contribution of Ednra-/- cells. In contrast, only one 
embryo that also had the highest number of Ednra-/- cells had a cardiovascular defect (Clouthier et al., 
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2003). This illustrates that cranial NCCs are far more sensitive to loss of EDNRA signaling than are 
cardiac NCCs, consistent with the findings in MFDA and ARCND individuals.  
 To date, variants within helix 8 of EDRRA in individuals with craniofacial malformations have not 
been identified. This may reflect sensitive or crucial functions of this helix that are not compatible 
with survival. In many class A GPCRs, including Endothelin receptor type B (EDNRB), ligand 
binding induces coordinated movements of transmembrane helix 7 and helix 8, along with other 
transmembrane helices, to expose the binding interface for the α5 helix of G protein α subunits (Weis 
& Kobilka, 2018). In the founding class A GPCR rhodopsin, the amino terminal end of helix 8 directly 
interacts with and activates Gα transducin (Scheerer et al., 2008). A potential consequence of the 
p.Q381P proline substitution is a distortion of the secondary structure or orientation of helix 8 that 
prevents EDN1-induced conformational transition of helix 7-helix 8. This model predicts that p.Q381P 
impairs the general G protein activation mechanism for EDNRA, accounting for the severe congenital 
anomalies. 
 In summary, we have found the first known homozygous loss-of-function variant in EDNRA. In 
vitro analysis of this allele illustrates that the variant disrupts G protein association with the receptor, 
which, in vivo, likely results in near-complete loss of EDNRA signaling and hence severe 
developmental defects in craniofacial and cardiovascular structures. From a clinical perspective, this 
case demonstrates a new, distinct phenotype that to our knowledge has not been previously described. 
The mandibular and oral findings have some overlap with syndromes caused by other genes in the 
endothelin pathway, including ARCND and MFDA, but the cardiac findings and severity of external 
ear differences may provide a clue to loss-of-function of EDNRA. This case highlights the utility of 
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combining neonatal or prenatal whole exome or whole genome sequencing with functional analysis of 
relevant variants in cases where a genetic condition is suspected, as identification of an etiology can 
inform future reproductive decisions for a family and ameliorate some of the guilt of grieving parents. 
In this case, the family has proceeded with pre-implantation genetic diagnosis to ensure a fetus is not 
homozygous for this variant in EDNRA and has had two healthy children through in vitro fertilization. 
Prompt functional investigations into candidate genes as performed here are crucial given the limited 
accessibility of pre-implantation genetic diagnosis, especially in the case of a candidate gene. With the 
emergence of well-established, sensitive, and modular BRET sensors, it should be possible to rapidly 
assess genetic variants of G protein signaling components that arise in exome or genome sequencing to 
both identify potential candidates for further functional analysis and to understand how the variants 
function at the cellular level. Additionally, because BRET assays do not require sophisticated 
instruments outside of a microplate reader that detects fluorescence and bioluminescence, this 
approach should be widely accessible to researchers and clinicians. Currently, the time-consuming 
aspect of this approach is assembling and validating sensors required for specific aspects of G protein 
signaling. In addition, each new genetic variant has to be introduced into the appropriate cDNA. 
However, as these approaches become more widespread, the turnaround time from variant 
determination to confirmation of BRET results can be under one month. While getting Clinical 
Laboratory Improvement Amendment (CLIA) certification for these assays would take time, our 
results will hopefully encourage more wide-spread biochemical analysis of neonatal-lethal craniofacial 
malformations. 
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Figure Legends 
 
Figure 1. Phenotypic and genomic analysis. (a) Anterior and (b) lateral views of the infant’s face 
demonstrating dysmorphic features including downslanting palpebral fissures, upturned nasal tip, thin 
upper lip, micrognathia, microstomia, and abnormal external ears. (c) Sanger sequencing confirmation 
of the c.1142A>C mutation in the proband, resulting in the p.Q381P variant. (d) Bubble diagram of the 
EDNRA (adapted from GPCRdb.org). The p.Q381P mutation in helix 8 is denoted in red. c-term, C-
terminus; ECL, extracellular loop; ICL, intracellular loop; n-term, N-terminus. 
 
Figure 2. The EDNRA p.Q381P variant cannot induce EDNRA-dependent gene expression. qRT-
PCR analysis of Dlx5 (A) and Dlx2 (B) gene expression in MC3T3-E1 cells following transfection 
with empty vector (mock), EDNRA or EDNRA p.Q381P and treatment with EDN1. (a) While 
addition of EDN1 resulted in upregulation of Dlx5 expression in cells with wild type EDNRA, Dlx5 
expression was not induced in cells with the EDNRA p.Q381P variant. (b) Addition of EDN1 resulted 
in downregulation of Dlx2 expression in cells with a wild type EDNRA but not in cells with the 
EDNRA p.Q381P variant (B). Assays were performed in duplicate or triplicate at least three times. 
Error bars represent SEM; two-tailed t-test; *p<0.05, **p< 0.005, ***p<0.001; ns., not significant.  
 
Figure 3. EDNRA subcellular localization and EDN1 binding is not disrupted by the p.Q381P 
variant. (a) Schematic of the BRET assay for subcellular localization, in which EDNRA-Renilla 
luciferase 8 (RLuc8) is combined with Venus (V)-kras (plasma membrane), Venus-PTP1B 
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(endoplasmic reticulum) or Venus-giantin (Golgi apparatus) to measure BRET in different cellular 
compartments. (b) Average net BRET of unstimulated HEK293 cells transfected with wildtype 
EDNRA-RLuc8 or EDNRA p.Q381P-RLuc8 and V-kras, V-PTPB1 or V-giantin. Assays were 
performed at least three times. Error bars represent SEM.; two-tailed t-test; n.s., not significant. (c) 
Confocal images of HEK293T cells transfected with mCherry-MEM and pcDNA3.1, wild type 
EDNRA or EDNRA p.Q381P and incubated with Hilyte fluor-488-ET-1. mCherry-MEM and Hilyte 
fluor-488-ET-1 co-localized within cells expressing wild type EDNRA or EDNRA p.Q381P but not in 
empty vector (mock)-transfected cells. Images are representative of ligand binding after a 5 minute 
incubation. Green and red channels represent Hilyte fluor-488-ET-1 and mCherry-MEM, respectively. 
(d) HEK293T cells transfected with empty vector (mock), wild type EDNRA or EDNRA p.Q381P 
were incubated with Hilyte fluor-488-ET-1 and quantitatively analyzed with a fluorescence microplate 
reader. Specific fluorescence was calculated by subtracting background fluorescence values (from 
empty wells treated with Hilyte fluor-488-ET-1) from the raw fluorescence values. Assays were 
performed in triplicate at least three times. Error bars represent SEM; two-tailed t-test *p < 0.05, **p< 
0.01; n.s., not significant.  
 
Figure 4. The EDNRA p.Q381P variant disrupts G protein activation. (a) Schematic for the G 
protein activation BRET reporter assay. EDN1-induced EDNRA activation promotes dissociation of 
the G protein heterotrimer to Gαq and Gβγ-Venus. Subsequent interaction of Gβγ-Venus with mas-
GRKct-nLuc produces BRET, which is an indirect reporter of G protein activation. (b) BRET assay in 
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HEK293T cells transfected with the BRET components shown in (a) and empty vector (mock), wild 
type EDNRA or EDNRA p.Q381P. Baseline BRET was measured for 30 seconds, at which time cells 
were treated with EDN1 (indicated by arrow) and measured for another 2 minutes. A robust EDN1-
induced BRET response was observed only in cells expressing wildtype EDNRA (blue trace). In the 
presence of EDNRA p.Q381P (orange trace), BRET was not statistically different from the presence 
of a mock vector (grey trace). Traces represent the average delta BRET of at least three independent 
transfections. Error bars at each timepoint represent SEM. (c) Maximum BRET response was 
quantified as the average of maximum delta BRET values elicited by EDN1. Assays were performed 
in triplicate at least three times. Error bars indicate SEM; two-tailed t-test; **p < 0.01, ***p< 0.005; 
n.s., not significant.  
 
Figure 5. The EDNRA p.Q381P variant disrupts G protein coupling. (a) Schematic of the BRET 
assay for G protein coupling. A Venus-mini G protein can associate with a wild type EDNRA-RLuc8 
after addition of EDN1, resulting in BRET. (b) The maximum BRET response was quantified for four 
classes of mini G proteins with wildtype EDNRA-RLuc8 or EDNRA-RLuc8 p.Q381P. Maximum 
BRET response for all mini G proteins was lower in cells expressing EDNRA-RLuc8 p.Q381P 
compared to wildtype EDNRA, though the change for mGs12 was not statistically significant 
(p=0.0678). Assays were performed in triplicate at least three times. Error bars indicate SEM; two-
tailed t-test ***p<0.005; ns, not significant.  
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Table 1. Phenotypes associated with mutations in Endothelin pathway genes 
 
Gene MIM Name/Number Inheritance Pattern Clinical Features 




Micrognathia, mandibular ankylosis, mandibular 
condyle hypoplasia, microstomia, glossoptosis, 
malformed ears (question mark ears),  
prominent cheeks, palate abnormalities 




Micrognathia, mandibular ankylsosis, 
mandibular condyle hypoplasia, microstomia, 
glossoptosis, malformed ears (question mark 
ears), prominent cheeks, palate abnormalities 




Micrognathia, mandibular hypoplasia, 
question mark ears, glossoptosis, bifid uvula, 
laryngeal cleft, lingual hamartomas 




Question mark ears 
EDNRA Mandibulofacial dysostosis 
with alopecia, #616367 
Autosomal 
dominant 
Micrognathia, cleft palate, maxillary 
hypoplasia, dysplastic zygomatic arch, limited 
jaw mobility, thin or absent scalp hair, low set 
ears, dysplastic ears, sparse eyebrows and 
eyelashes, scant body hair, conductive 
hearing loss 
EDNRA N/A (this manuscript) Autosomal 
recessive 
Micrognathia, microstomia, microtia/anotia, 
absent middle ear structures, aglossia, 
oropharyngeal stenosis, absent soft palate 
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Table 2. Physical Examination and Autopsy Findings 
 
Organ System Findings 
Facial Long, downslanting palpebral fissures 
Increased outer canthal distance 
Fused eyelids 
Upturned nasal tip 
Upper lip hypoplasia 
Ears Microtia/anotia 
Absent external auditory canal 
Absent middle ear structures 
Mouth Micrognathia 
Microstomia 
Aglossia (no skeletal muscle present, only squamous mucosa) 
Maxillary-like appearance to lower jaw 
Severe posterior oropharyngeal stenosis 
Absent soft palate and uvula 
Grooved hard palate 
Cardiovascular Hypoplastic aortic arch 
VSD with posterior malalignment 
Bicuspid aortic valve 
Retroesophageal right subclavian artery 
Respiratory Right lung with azygous lobe 
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